Psivida feeling no pain
06 August, 2004 by Graeme O'NeillPerth nano-biotech company pSivida has been keeping its patent lawyers in the UK from their repose, with the company announcing that its UK subsidiary, Psimedica, has been issued with yet another US patent for its proprietary biomaterial BioSilicon.
Progen's Lee denies partnering rumours
06 August, 2004 by Melissa TrudingerProgen's (ASX: PGL) CEO Lewis Lee confirmed today that its partnering strategy, as announced at last year's AGM, was proceeding on track, but that no agreements are pending.
Eiffel to raise $3 million
06 August, 2004 by Renate KrelleShares in Sydney drug re-engineering company Eiffel Technologies (ASX: EIF) slumped today when the company announced a capital raising of AUD$3.0 million, placing 36.4 million fully paid ordinary shares at 8.25 cents per share.
Biobanks a must for personalised medicine
06 August, 2004 by Melissa TrudingerFuture drug development efforts are likely to depend heavily on access to patient and clinical data, according to IBM's Dr Bruce Ross, who gave a keynote speech at the recent Health Informatics Conference 2004 held in Brisbane.
C3 raises $10 million, readies for product launch
05 August, 2004 by Melissa TrudingerClinical Cell Culture (C3; ASX: CCE) has completed an AUD$9.8 million placement to Australian institutional and sophisticated investors to help fund the company's expansion into European and US markets.
Macquarie start-up Applimex seeks extreme solutions for industry
05 August, 2004 by Graeme O'NeillNew Sydney biotechnology company Applimex Systems, Macquarie University’s latest spin-off, is commercialising microbes that, in the modern tabloid lexicon, qualify as 'superbugs'.
Imugene crows over immune booster
05 August, 2004 by Graeme O'NeillMicrobiologists warned nearly three decades ago that antibiotics used as livestock growth promoters were a human health hazard.
Select Vaccines boosted by licensing agreement
04 August, 2004 by Melissa TrudingerSelect Vaccines (ASX: SLT) shares jumped 18 per cent to close at AUD$0.33 yesterday after the company announced it had successfully reached an agreement to license its hepatitis E laboratory and point-of-care diagnostic tests to Genelabs Diagnostics.
Extreme makeovers: body-bits and injectable scaffolds
04 August, 2004 by Graeme O'NeillNew Melbourne-based biotechnology company PolyNovo Biomaterials has gone into the body-bits business -- with a material straight from the surgery of the Starship Enterprise.
Regenera sees new applications for technology
04 August, 2004 by Melissa TrudingerRegenera (ASX:RGA) has picked up three new applications for ocular applications of its core product Visagen, a proprietary formulation of synthetic steroid triamcinolone acetonide.
Regenera set to begin Singapore trials
03 August, 2004 by Melissa TrudingerRegenera (ASX: RGA) has received ethics committee approval to begin Phase III human clinical trials for its synthetic steroid drug Visagen at the Singapore Eye Research Institute.
FDA OK's higher dose of Starpharma's VivaGel
03 August, 2004 by Melissa TrudingerStarpharma (ASX: SPL) will move to the next stage of the Phase I clinical trial for its nanodendrimer-based vaginal microbicide VivaGel, after the US FDA approved a dose increase based on the interim trial results.
Biotech IPOs continue to provide excellent returns
02 August, 2004 by Michael VitaleInvestors in the initial public offerings (IPOs) of Australian biotechnology companies have done well over the past six years -- despite the fact that the shares of most of the newly listed companies are currently trading below the price at which they were first sold.
Meditech announces new CEO, chairman
02 August, 2004 by Melissa TrudingerMeditech Research (ASX: MTR) has appointed former CSL and Millennium Pharmaceuticals executive Dr Ian Nisbet as CEO to replace Chris Carter who stepped down on Friday, after a shareholder stoush in April forced his resignation.
Chemeq plant finally operational
02 August, 2004 by Renate KrelleProduction facilities at Chemeq (ASX:CMQ) have finally come to life, with the company announcing that it has manufactured enough of the active pharmaceutical ingredient of its novel antimicrobial to verify the production process.
